Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice
Authors
Keywords
Administration-related reactions, Plasma cell disorders, Recombinant hyaluronidase, Tolerability, Best-practices
Journal
Clinical Lymphoma Myeloma & Leukemia
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-03-08
DOI
10.1016/j.clml.2021.02.014
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Daratumumab Plus CyBorD for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA
- (2020) Giovanni Palladini et al. BLOOD
- Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol
- (2020) Issam S. Hamadeh et al. Clinical Lymphoma Myeloma & Leukemia
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
- (2020) Maria-Victoria Mateos et al. Lancet Haematology
- Safety of ninety-minute daratumumab infusion
- (2020) Jeffrey Lombardi et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Daratumumab Plus Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- (2019) Ajai Chari et al. BLOOD
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer
- (2019) Christian Jackisch et al. JAMA Oncology
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
- (2019) Maria-Victoria Mateos et al. LANCET
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
- (2018) Andrew Spencer et al. HAEMATOLOGICA
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search